Equities research analysts forecast that Heron Therapeutics Inc (NASDAQ:HRTX) will report earnings of ($0.46) per share for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Heron Therapeutics’ earnings, with estimates ranging from ($0.60) to ($0.34). Heron Therapeutics reported earnings of ($0.97) per share in the same quarter last year, which suggests a positive year over year growth rate of 52.6%. The business is scheduled to announce its next earnings results on Tuesday, February 26th.

According to Zacks, analysts expect that Heron Therapeutics will report full year earnings of ($2.26) per share for the current fiscal year, with EPS estimates ranging from ($2.52) to ($1.98). For the next financial year, analysts forecast that the business will report earnings of ($0.67) per share, with EPS estimates ranging from ($1.44) to $0.45. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Heron Therapeutics had a negative net margin of 326.79% and a negative return on equity of 72.23%. The business had revenue of $19.79 million during the quarter, compared to analyst estimates of $19.84 million. During the same quarter in the prior year, the business earned ($0.77) earnings per share. The firm’s revenue was up 130.9% compared to the same quarter last year.

Several research firms recently commented on HRTX. Cantor Fitzgerald restated a “buy” rating and issued a $50.00 target price on shares of Heron Therapeutics in a research report on Wednesday, August 8th. ValuEngine cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 4th. Zacks Investment Research upgraded Heron Therapeutics from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a research report on Wednesday, July 18th. Stifel Nicolaus started coverage on Heron Therapeutics in a research report on Thursday, September 13th. They set a “buy” rating and a $55.00 price target on the stock. Finally, BidaskClub cut Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company. Heron Therapeutics has an average rating of “Buy” and a consensus price target of $52.09.

HRTX opened at $27.16 on Wednesday. Heron Therapeutics has a 12 month low of $14.95 and a 12 month high of $42.90. The company has a market capitalization of $2.21 billion, a P/E ratio of 7.44 and a beta of 1.45.

In other news, VP Kimberly Manhard sold 6,000 shares of the firm’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $32.07, for a total value of $192,420.00. Following the completion of the sale, the vice president now owns 6,000 shares of the company’s stock, valued at $192,420. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kevin C. Tang sold 2,695,000 shares of the firm’s stock in a transaction on Wednesday, September 12th. The stock was sold at an average price of $35.75, for a total value of $96,346,250.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,701,494 shares of company stock valued at $96,553,796. 16.20% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of the company. Allianz Asset Management GmbH boosted its position in Heron Therapeutics by 1,040.8% during the third quarter. Allianz Asset Management GmbH now owns 1,887,391 shares of the biotechnology company’s stock valued at $59,736,000 after purchasing an additional 1,721,947 shares during the last quarter. BlackRock Inc. boosted its position in Heron Therapeutics by 29.4% during the second quarter. BlackRock Inc. now owns 4,544,731 shares of the biotechnology company’s stock valued at $176,563,000 after purchasing an additional 1,032,010 shares during the last quarter. Rubric Capital Management LP boosted its position in Heron Therapeutics by 71.8% during the third quarter. Rubric Capital Management LP now owns 1,958,850 shares of the biotechnology company’s stock valued at $61,998,000 after purchasing an additional 818,603 shares during the last quarter. FMR LLC boosted its position in Heron Therapeutics by 6.5% during the second quarter. FMR LLC now owns 11,290,956 shares of the biotechnology company’s stock valued at $438,654,000 after purchasing an additional 693,699 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in Heron Therapeutics during the second quarter valued at $15,249,000.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Read More: Cost of Debt

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.